JulyMD: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://julymd.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.

1. 1

   “"Our Semaglutide injection, featuring the same active ingredient as Wegovy and Ozempic, offers a powerful solution."”

2. 2

   “"Yes, Semaglutide is the active ingredient in Ozempic and Wegovy, a medication commonly used to manage type 2 diabetes and support weight loss. If you're looking for an affordable alternative, consider trying our compounded Semaglutide. It offers the same effective ingredient as Ozempic and Wegovy, but at a fraction of the price."”

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

julymd.com returned a live storefront when we checked in August 2026, still running a semaglutide weight-loss programme alongside a lipotropic injection and an anti-aging line.

Most of the copy FDA quoted across this roster is banner text. This is a customer-service answer, and that changes how it should be read: the passage FDA objected to is what the company told someone who had already asked whether the cheap version is the same thing. Its structure is the one every price shopper eventually builds for themselves — same ingredient, therefore same drug, therefore the price difference is the only difference. FDA's position is that the middle step does not hold, because approval attaches to a finished product and not to a molecule. The price gap is real and worth chasing. The claim this page attached to it, that nothing but the price is different, is the part FDA said was not established.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence JulyMD failed to respond.